Navigation Links
NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
Date:3/24/2008

IRVINE, Calif., March 24 /PRNewswire-FirstCall/ -- NuRx Pharmaceuticals, Inc. (OTC Bulletin Board: NURX) today announced it has dosed the first patient in a Phase I clinical trial of the first-in-class rexinoid receptor (RXR) agonist NRX4204.

The single-center study, which NuRx expects to complete in the fourth quarter of this year, is designed to evaluate the safety and tolerability of the compound. NRX4204 is the company's first drug candidate in clinical trials.

"Our preclinical data show that NRX4204 is a highly potent and specific, orally bio-available RXR agonist that is effective in models of non-small cell lung cancer and breast cancer," said Harin Padma-Nathan, M.D., NuRx's president and CEO. "We intend to pursue the development of this compound as a treatment for both indications. There are no rexinoid treatments currently approved for these indications."

NuRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation retinoid and rexinoid compounds for application in oncology (treatment, prevention and adjunctive supportive therapy) and other highly prevalent diseases. The company's lead compounds are NRX4204, a highly specific, first-in-class rexinoid agonist that is targeted for development in non-small cell lung carcinoma and breast cancer and a RAR agonist for the treatment of acute leukemia. Based in Irvine, Calif., NuRx has a technology and IP platform that includes a library of nearly 6,000 compounds supported by 230 issued U.S. and international patents and more than 80 additional patents in application. For more information, visit http://www.nurxpharmaceutical.com.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management. Th
'/>"/>

SOURCE NuRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced a ... use in portable vaporizers, which contains CBD, or ... cannabis, cannabidiol offers consumers a THC-free product made ... vaporizer technology. Photo - http://photos.prnewswire.com/prnh/20140711/126344 ... different compounds which are currently known, two of ...
(Date:7/11/2014)... HILL, N.C. , July 11, 2014 /PRNewswire/ ... of pharmaceutical marketing and, consequently, organizations are turning ... for patients. As part of this ... it,s important to educate, communicate and engage patients ... disease awareness to patient empowerment. By mapping the ...
(Date:7/11/2014)... CHAPEL HILL, N.C. , July 11, 2014 ... research analysis approaches are evolving across industry sectors ... are now examining better ways to engage with ... how consumers inform themselves and make critical purchasing ... by benchmarking firm, Best Practices, LLC, one area ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... Mass., March 18, 2011 Cytel ... implementation services and software, proudly announced today the ... Baker as Vice President, Clinical Research Services. ... demonstrated biopharmaceutical development leadership at some of the ...
... family of Midland, Michigan have a new lease on ... and Mike ALL underwent Roux-en-Y bariatric surgery ... to offer this life-changing surgery. The surgeries were performed ... The family has lost 445 pounds, and counting. ...
Cached Medicine Technology:Cytel Hires Biopharmaceutical Development Veteran Jim Baker to Support Expansion of its Clinical Research Offerings 2Midland Family Undergoes Bariatric Surgery at Hurley Medical Center--Loses 445 Pounds & Counting—Tells their Life-Saving Story to Media on March 18, 2011 2
(Date:7/13/2014)... July 13, 2014 Max International ... Chris Mullin, will be the featured guest at its ... in Puerto Rico. Attendees will learn about Max’s ... in two exhibition basketball games and perform in a ... supplier of health- and energy-boosting supplements , has recently ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Recently, MyDressCity.com, ... and women’s special occasion outfits, has released its new ... all the new products are available at discounted prices. ... 26, 2014. , In the company’s online shop, ... all of them are made with great materials. MyDressCity.com’s ...
(Date:7/13/2014)... Fadhits.com is popular among worldwide women. Its ... beautiful. Recently, the company has announced its new selection ... more, all these outfits are available at discounted prices ... the supplier is now offering similar discounts for many ... has many other designs for sale, including flower girl ...
(Date:7/13/2014)... Epidemiologists forecast an increase in the ... 8,062 diagnosed incident cases in 2013 to 11,568 diagnosed ... (AGR) of 4.35%, during the forecast period. In 2023, ... incident cases of aGVHD in the 6MM, with 4,989 ... number of diagnosed incident cases of aGVHD, with 704 ...
(Date:7/13/2014)... optical imaging device developed at Cedars-Sinai can provide ... the brain and are a classic sign of ... conducting a clinical trial in Australia. , The ... an oral presentation at the Alzheimer,s Association International ... invited by conference organizers to participate in a ...
Breaking Medicine News(10 mins):Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3
... that are becoming increasingly common as a first line of ... the kidneys may not be necessary, according to a new ... The study shows that the condition, known as ... a very small percentage of cases and does not always ...
... Speaker Nancy Pelosi, Congressman Chris Van Hollen, ... youth organizations from 30 states for a press conference ... provision impacting young adults in health insurance reform legislation. ... their parents, insurance through the age of 26. Also ...
... D. Porpoise Evans, a litigation associate in the Miami ... been named among the "40 Under 40" outstanding lawyers of ... lawyers will be honored at the CFF benefit dinner on ... "Porpoise,s recognition as one of Miami-Dade County,s top up-and-coming young ...
... Zones Vitality Project Inspired Residents to Make Simple Changes, ... 13 The AARP(R)/Blue Zones(R) Vitality Project sponsored ... life expectancy of the citizens of Albert Lea increased ... unprecedented 10-month city-wide health makeover. The project was ...
... Senate Finance Committee,s approval of an ambitious health reform plan ... health care to tens of millions of people who lack ... or face exorbitant charges, and begin to address the nation,s ... care costs. , The Congressional Budget Office has reported that ...
... , MONROVIA, Calif. and HANGZHOU, China, Oct. 13 ... the "Company") (OTC Bulletin Board: NIUS), a leading U.S.-based ... for children, today announced that the Company successfully launched ... prior to the national holiday week in China. ...
Cached Medicine News:Health News:Study questions need for routine intervention in patients with renovascular disease 2Health News:Study questions need for routine intervention in patients with renovascular disease 3Health News:Pelosi Announces Key Provision in Health Insurance Reform for Young Adults 2Health News:Pelosi Announces Key Provision in Health Insurance Reform for Young Adults 3Health News:Pelosi Announces Key Provision in Health Insurance Reform for Young Adults 4Health News:Pelosi Announces Key Provision in Health Insurance Reform for Young Adults 5Health News:Pelosi Announces Key Provision in Health Insurance Reform for Young Adults 6Health News:Cystic Fibrosis Foundation Names Greenberg Traurig Attorney D. Porpoise Evans Among the '40 Under 40' Outstanding Lawyers of Miami-Dade County 2Health News:Albert Lea Residents Add 3.1 Years of Life Expectancy 2Health News:Albert Lea Residents Add 3.1 Years of Life Expectancy 3Health News:Albert Lea Residents Add 3.1 Years of Life Expectancy 4Health News:Albert Lea Residents Add 3.1 Years of Life Expectancy 5Health News:Statement of Robert Greenstein, Executive Director, Center on Budget and Policy Priorities, on The Senate Finance Committee's Health Reform Plan 2Health News:Statement of Robert Greenstein, Executive Director, Center on Budget and Policy Priorities, on The Senate Finance Committee's Health Reform Plan 3Health News:Niusule Launches 'Niusule Gummy Bears' in China 2Health News:Niusule Launches 'Niusule Gummy Bears' in China 3
... Series I Instrument program offers state-of-the-art quality ... while maintaining strength and durability. Low profile ... tight joint spaces. Series I instruments are ... style, size and angle required for large ...
... offers state-of-the-art quality in an instrument of ... durability. Low profile cutting tips allow access ... I instruments are available in just about ... required for large and small joint arthroscopic ...
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
... The Series I Instrument program offers ... low profile, while maintaining strength and durability. ... pathology in tight joint spaces. Series I ... cutting tip style, size and angle required ...
Medicine Products: